Anti-CD20 agent has been proposed as a rescue therapy for refractory nephrotic syndrome(NS)
on the basis of favorable clinical observations. Yet the long-term effect on maintaining
remission or the likelihood of becoming rituximab-dependent is unclear and the information on
the safety profile of rituximab is limited. This trial was designed to investigate the safety
and efficacy of Rituximab in children with refractory NS.